Market Overview

Amicus Extending Rally On Upgrades

Related FOLD
5 Biotechs Leerink Analysts Are Watching
Mid-Morning Market Update: Markets Gain; Finish Line Beats Q1 Views

Amicus Therapeutics (NASDAQ: FOLD) shares are up 12 percent Tuesday following a nine percent jump Monday.

This move comes after JP Morgan, Janney and Leerink Partners upgraded Amicus to buy Monday and Tuesday and significantly boosted their price targets. The median price target is $5.50, or 45.1 percent of additional upside (65 percent before the stocks started moving higher).

Leerink thinks that the Phase 3 study has a high chance for success: 75 percent in Europe and 50 percent in the United States. This compares to a 20 percent success rate previously.

Related: Exclusive: Hepatitis C Stock Valuation With Enanta CEO Jay Luly

Leerink also expects top line results from study 012 at the end of July or beginning of August.

Shares of Amicus Were last trading up 12.5 percent in Tuesday’s pre-market session to $3.76. Shares have risen more than 42 percent in value year-to-date.

Latest Ratings for FOLD

Jun 2015B RileyMaintainsBuy
May 2015Chardan CapitalInitiates Coverage onBuy
Mar 2015Leerink SwannMaintainsOutperform

View More Analyst Ratings for FOLD
View the Latest Analyst Ratings

Posted-In: Janney JP Morgan LeerinkUpgrades Movers & Shakers Price Target Analyst Ratings General


Related Articles (FOLD)

View Comments and Join the Discussion!

Get Benzinga's Newsletters